tirzepatide in type 1 diabetes The evidence for GLP-1 receptor agonists is no longer sparse. It is growing — and it is specific.ADJUST-T1D. TIRTLE1. Two years of real-world data. Meta-analyses pooling hundreds of Efficacy and safety of tirzepatide

For the people at the center of this litigation, it represents an attempt to hold a pharmaceutical manufacturer accountable for what they allege was an inadequate warning system around a drug that affected their health in lasting, serious ways

Paul is a great doctor

Currently, there seem to be supportive data that GLP-1 RAs can have beneficial outcomes in neurodegenerative diseases such as PD

They initially focused exclusively on brand-name Wegovy and Ozempic, offering insurance concierge services to help patients secure coverage

far more potent in preclinical work

Kudlaty E, Perez M, Stein BL, Bochner BS, Kuang FL